Rizonib
Generic Name
Rizonib
Manufacturer
Acme Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| rizonib 250 mg capsule | ৳ 750.00 | ৳ 7,500.00 |
Description
Overview of the medicine
Rizonib 250 mg capsule is a targeted therapy used in oncology. It belongs to the class of tyrosine kinase inhibitors, which work by blocking specific proteins that promote cancer cell growth and division.
Uses & Indications
Dosage
Adults
250 mg once daily, taken with or without food. Dosage adjustments may be required based on tolerability and response.
Elderly
No specific dosage adjustment required, but monitor for adverse effects.
Renal_impairment
No dosage adjustment needed for mild to moderate renal impairment. Use with caution in severe impairment.
How to Take
Swallow capsules whole with water. Do not open, crush, or chew. Can be taken with or without food.
Mechanism of Action
Rizonib selectively inhibits specific receptor tyrosine kinases involved in cell proliferation, angiogenesis, and metastasis. By binding to the ATP-binding site of these kinases, it prevents downstream signaling pathways, leading to inhibition of tumor growth and survival.
Pharmacokinetics
Onset
Clinical effects typically observed within weeks of initiation.
Excretion
Mainly excreted via feces (approximately 70%) and urine (approximately 30%).
Half life
Approximately 18-24 hours.
Absorption
Well absorbed orally, peak plasma concentrations reached within 2-4 hours.
Metabolism
Primarily metabolized in the liver by CYP3A4.
Side Effects
Contraindications
- Hypersensitivity to Rizonib or any excipients
- Severe hepatic impairment
Drug Interactions
Strong CYP3A4 inducers
Co-administration with strong CYP3A4 inducers (e.g., rifampicin, phenytoin) may decrease Rizonib concentrations, reducing efficacy. Avoid concomitant use.
Strong CYP3A4 inhibitors
Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase Rizonib concentrations, leading to increased risk of adverse events. Consider dose reduction or alternative therapy.
Proton Pump Inhibitors (PPIs)
May reduce absorption of Rizonib, particularly if Rizonib requires an acidic environment for absorption. Consider H2-receptor antagonists or antacids with caution, separating administration times.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with Rizonib overdose. Expected symptoms include exaggerated side effects such as severe gastrointestinal disturbances, hepatotoxicity, and dermatologic reactions. Management should be supportive, including monitoring vital signs and treating symptoms. No specific antidote is available.
Pregnancy & Lactation
Pregnancy Category D. May cause fetal harm. Advise women of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Breastfeeding is not recommended during treatment and for 3 months after the last dose due to potential harm to the infant.
Side Effects
Contraindications
- Hypersensitivity to Rizonib or any excipients
- Severe hepatic impairment
Drug Interactions
Strong CYP3A4 inducers
Co-administration with strong CYP3A4 inducers (e.g., rifampicin, phenytoin) may decrease Rizonib concentrations, reducing efficacy. Avoid concomitant use.
Strong CYP3A4 inhibitors
Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase Rizonib concentrations, leading to increased risk of adverse events. Consider dose reduction or alternative therapy.
Proton Pump Inhibitors (PPIs)
May reduce absorption of Rizonib, particularly if Rizonib requires an acidic environment for absorption. Consider H2-receptor antagonists or antacids with caution, separating administration times.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with Rizonib overdose. Expected symptoms include exaggerated side effects such as severe gastrointestinal disturbances, hepatotoxicity, and dermatologic reactions. Management should be supportive, including monitoring vital signs and treating symptoms. No specific antidote is available.
Pregnancy & Lactation
Pregnancy Category D. May cause fetal harm. Advise women of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Breastfeeding is not recommended during treatment and for 3 months after the last dose due to potential harm to the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date
Availability
Specialty pharmacies, Hospitals
Approval Status
Approved by regulatory bodies
Patent Status
Under patent
Clinical Trials
Phase III trials demonstrated significant improvement in progression-free survival compared to placebo in advanced NSCLC patients with specific mutations. Ongoing studies are evaluating its efficacy in other solid tumors.
Lab Monitoring
- Complete blood count (CBC) with differential
- Liver function tests (ALT, AST, bilirubin)
- Renal function tests (creatinine, BUN)
- Electrolytes (potassium, magnesium)
Doctor Notes
- Emphasize patient education on adverse event reporting.
- Regular monitoring of liver function, blood pressure, and skin is crucial.
- Consider drug interactions carefully, especially with CYP3A4 modifiers.
Patient Guidelines
- Take Rizonib exactly as prescribed by your doctor.
- Do not stop taking the medicine without consulting your doctor.
- Report any severe side effects immediately to your healthcare provider.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is less than 12 hours before the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose.
Driving Precautions
Rizonib may cause fatigue, dizziness, or visual disturbances. Patients should be cautioned against driving or operating machinery if they experience these symptoms.
Lifestyle Advice
- Maintain good hydration.
- Avoid direct sun exposure and use sunscreen due to increased photosensitivity.
- Follow a balanced diet and consult with a nutritionist if experiencing significant appetite loss.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.